NCT04603586已完成不适用
A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (<70gy vs. >70Gy) in Locally Advanced Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 119
- 试验地点
- 2
- 主要终点
- Progression-Free-Survival
研究概览
简要总结
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (<70Gy Vs.>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cytologically or histologically verified pancreatic adenocarcinoma
- •Imaging examinations confirmed locally advanced pancreatic cancer
- •No previous radiotherapy, chemotherapy, immunotherapy or targeted therapy
- •ECOG of 0 to1
- •Age of 18 years or older
- •Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) ≥ 1.5×10^9 cells/L, leukocyte count≥ 3.5×10^9 cells/L, platelets ≥ 70×10^9 cells/L, hemoglobin ≥ 8.0 g/dl
- •Adequate liver and renal, defined as: Albumin > 2.5 g/dL, total bilirubin < 3 mg/dL, creatinine < 2.0 mg/dL, AST<2.5 × ULN (Upper Limit of Normal) (0-64U/L), ALT<2.5 × ULN (0-64U/L)
- •Adequate blood clotting function, defined as: international normalized ratio (INR) < 2 (0.9-1.1)
- •Ability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document
排除标准
- •Previously receiving radiotherapy, immunotherapy or targeted therapy
- •Evidences of metastatic disease confirmed by chest CT or PET-CT
- •Age <18 years
- •Secondary malignancy
- •Abnormal results of blood routine examinations and liver and kidney and coagulation tests
- •Patients with active inflammatory bowel diseases or peptic ulcer
- •Gastrointestinal bleeding or perforation within 6 months
- •Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
- •Medical history of symptomatic congestive heart failure: New York Heart Association Class III to IV
- •Medical history of respiratory insufficiency
- •Women who are pregnant or breastfeeding
- •Participation in another clinical treatment trial
- •Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document
研究组 & 干预措施
Arm A
Active Comparator
SBRT of BED<70Gy combined with Gemcitabine + albumin-bound paclitaxel
干预措施: SBRT (Radiation)
Arm A
Active Comparator
SBRT of BED<70Gy combined with Gemcitabine + albumin-bound paclitaxel
干预措施: Chemotherapy (Drug)
Arm B
Experimental
SBRT of BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
干预措施: SBRT (Radiation)
Arm B
Experimental
SBRT of BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Progression-Free-Survival
时间窗: 3 years
Progression-Free-Survival
次要结局
- Overall Survival(3 years)
- Adverse Events(3 years)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell CarcinomaRenal Cell CarcinomaNCT02138578University of Michigan Rogel Cancer Center4
Unknown
不适用
Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal MassesSmall Renal Masses (SRM)NCT03811665St. Joseph's Healthcare Hamilton24
Unknown
2 期
Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung CancerNSCLCNCT02975609Shanghai Chest Hospital100
已完成
不适用
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian CancerOvarian NeoplasmsRecurrent Ovarian CarcinomaOligometastatic DiseaseNCT04593381Gemelli Molise Hospital376
尚未招募
不适用
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)EGF-R Positive Non-Small Cell Lung CancerNon Small Cell Lung CancerEGFR Exon 19 DeletionEGFR Exon 21 MutationEGFR G719XNCT05998993Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo35